Article

Eye tissue shortage may affect clinical research

Rockville, MD-The future of clinical ophthalmology may be uncertain due to a decrease in the number of human donor eyes provided by U.S. eye banks, according to the results of a recent survey.

Rockville, MD-The future of clinical ophthalmology may be uncertain due to a decrease in the number of human donor eyes provided by U.S. eye banks, according to the results of a recent survey.

Christine A. Curcio, PhD, of the Association for Research in Vision and Ophthalmology's (ARVO) Research Tissue Acquisition Working Group (RTAWG), led the survey of 240 U.S. ARVO members. The group found that cost and lack of availability of tissue meeting stringent criteria were the major factors among those surveyed.

Over the last decade, federal and state regulations severely impacted the availability of human eye tissue for research, the group said. Even some local laws are affecting individual eye bank practices, according to the group.

"Nowhere do impediments to obtaining human eyes for research have more impact than in the effort to understand age-related macular degeneration," said Dr. Curcio, professor of ophthalmology, University of Alabama, Birmingham. "Macular degeneration, an advanced form of which now has treatment options, still lacks a laboratory animal model that displays the full range of pathology typifying the human disorder. Thus, human tissues are particularly critical."

The survey results are published in Investigative Ophthalmology & Visual Sciences (2006;47:2747-2749).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.